What caused the significant net loss in the third quarter of 2002?

The substantial net loss of $2.6 billion for the third quarter of 2002 was primarily due to a one-time charge of $3.0 billion for acquired in-process research and development (IPR&D) related to the acquisition of Immunex Corporation. This charge reflects the estimated fair value of IPR&D projects acquired that had not yet reached technological feasibility and had no alternative future use.

How did the acquisition of Immunex Corporation impact Amgen's financial position?

The acquisition of Immunex significantly expanded Amgen's balance sheet. It resulted in a substantial increase in intangible assets (to $4.9 billion from $34 million) and goodwill (to $9.8 billion from $97 million). The company also recorded a large charge for IPR&D. Operationally, Immunex's products, notably ENBREL®, were consolidated into Amgen's reporting starting from July 16, 2002, contributing to revenue growth.

Despite the net loss, what are the positive signs in Amgen's financial performance for Q3 2002?

Despite the net loss driven by the IPR&D charge, Amgen's underlying business showed strong growth. Total revenues increased by 49% year-over-year, reaching $1.5 billion. Product sales grew by 53% to $1.35 billion, driven by strong performance from key products like EPOGEN®, Aranesp®, and the newly acquired ENBREL®. The company also saw an increase in cash from operations, strengthening its liquidity.

What is the outlook for Amgen's key products, particularly in light of the Immunex acquisition?

Amgen expects future growth to be driven by new products, notably Aranesp®, Neulasta™, and the newly acquired ENBREL®. While EPOGEN® sales are expected to grow modestly from patient population and price increases, Aranesp® and Neulasta™ have seen recent approvals and launches, with further expansion anticipated. ENBREL® is a significant addition to Amgen's portfolio, though its supply was constrained at the time of the filing. The company is actively working to increase ENBREL® manufacturing capacity.

AMGN 10-Q Quarterly Report Q3 FY2002 — Revenue, Net Income, EPS

Summary

Amgen Inc. reported a significant net loss of $2.6 billion for the third quarter of 2002, largely driven by a substantial $3 billion charge for acquired in-process research and development related to the acquisition of Immunex Corporation. Despite this net loss, the company experienced strong revenue growth, with total revenues increasing by 49% year-over-year to $1.5 billion in the quarter, primarily due to the inclusion of Immunex's results and strong performance from core products like EPOGEN® and Aranesp®. Operationally, Amgen's core business demonstrated resilience. Product sales, excluding the impact of Immunex's acquired products, grew by 33% in the quarter. The company also successfully integrated Immunex, which contributed ENBREL® sales from mid-July onwards. While the significant goodwill and intangible assets recorded from the Immunex acquisition will impact future financials through amortization and potential impairment testing, the strategic rationale for the acquisition points towards a strengthened market position. Investors should closely monitor the integration progress and the impact of the substantial acquired R&D charge on profitability.

Key Highlights

1Q3 2002 Net Loss of $2.6 billion, primarily due to a $3.0 billion charge for acquired in-process R&D related to the Immunex acquisition.
2Total revenues increased 49% to $1.5 billion in Q3 2002 compared to $1.0 billion in Q3 2001.
3Product sales grew 53% to $1.35 billion in Q3 2002 compared to $880 million in Q3 2001.
4Acquisition of Immunex Corporation completed on July 15, 2002, significantly increasing intangible assets and goodwill on the balance sheet.
5EPOGEN® sales grew 8% in Q3 2002, driven by demand and price increases.
6Aranesp® sales were $113.7 million in Q3 2002, benefiting from recent approvals and launches.
7ENBREL® sales, acquired with Immunex, contributed $158.1 million in Q3 2002.
8Significant increase in cash and cash equivalents to $1.16 billion from $689 million at the end of 2001, aided by operating activities and financing.

AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2002

Summary

Key Highlights

Frequently Asked Questions